Perspective
A series of recent developments in Bayesian multivariate modelling has emphasised the relevance and utility of structured, sparsity-inducing hierarchical models in a variety of multivariate contexts and applied gene expression studies. We review and exemplify some of this methodology here, utilising two current cancer genomics projects to provide illuminating examples. The main methodological foci are as follows:
• A novel hierarchical "sparsity prior" for variable/effect selection in highly multivariate models, and its use and application in multivariate regression and ANOVA when many of the regression parameters and effects are expected to be zero ([1] ); • The use of such sparsity priors in connection with regressions for genesample specific normalisation to correct for multiple components of non-biological error and bias in expression intensity estimates -referred to as "assay artifacts" ([1, 2] ); and • The use of such sparsity priors in Bayesian latent factor models for parsimonious representation of expression profiles and deconvolution of the complexities of patterns of covariation among genes that are potentially related to underlying pathway interactions as well as experimental influences ([2, 3] ).
Over the last several years, the development of larger and richer genomic studies -both experimental and observational -has motivated a number of developments that underlie the current work. The decreasing costs of DNA microarray assays are leading to larger and richer data sets from observational studies in human cancers and other areas, and advances in molecular technologies such as siRNA are leading to rapid increase in the scale and complexity of designed experiments in which genome-scale gene expression (and other) data is the response variable. Across all such studies, the concept of pattern profiling and expression signature identification are central: it is now common for analyses to utilise aggregate measures of gene expression on a selection of defined subsets of genes as characterising multiple aspects of either an underlying response to a biological intervention ([4, 5, 6, 7] ), or empirical prognostic markers in observational and clinical studies ([8, 9, 10, 11, 12, 13, 14, 15, 16, 17] ).
The two examples here provide specificity and context. The first data set comes from [6] , where experiments using primary breast epithelial cells generate expression profiles that are used to identify subsets of genes that show transcriptional responses to the action of a known oncogenic activity. Each oncogene intervention is replicated several times and the responses are evaluated using Affymetrix U133+ DNA microarray data. Resulting selected subsets of genes -or metagenes, one for each oncogene response -are then explored in gene expression data sets from human tumours, where summary patterns of aggregate gene expression variations of these "oncogene signatures" may have prognostic or therapeutic significance. This study builds on the development of this general concept in biological pathway interrogation and disease studies [4, 5, 7] . The example highlights the need for sensitive evaluation of which of the thousands of genes are truly transcriptionally responsive, emphasises the need for care that false discovery be minimised, and promotes attention to questions of data quality, comparability, and the likely need for within-model correction for systematic, non-biological biases and artifacts.
The second data set consists of expression profiles from human breast cancer tissues from a program with multiple clinical and basic pathway identification goals (e.g., [11, 15] ). The example here concerns the complexity of structure in patterns of association among hundreds of genes connected to the key breast cancer hormonal and growth pathways linked to ER (oestrogen receptor) and HER2/ERB-B2 proteins, each of interest in connection with improved therapeutics in breast cancer. One interest is the potential for tumour-derived gene expression measures to provide increasingly accurate, and higher-resolution, evaluation of the status of these pathways; hence the interest in gene subsets related to transcriptional variation within these pathways. This links intimately with the prognostic interests in improved gene expression signatures as covariates in predictive models ([15] ).
In the first example, the primary interest is ANOVA/regression modelling to identify gene subsets related to each of the interventions, and to account for artifactual effects in expression profiles across samples. The second example focuses on deconvolution of expression associations in a multivariate latent factor framework, again taking into account potential artifactual effects, and links in a predictive regression component to relate latent factors underlying gene expression across the ER and HER2 pathways to the (noisy) pathological measures of ER and HER2 status at the protein level using traditional immunohistochemistry. The over-arching sparse factor regression model context subsumes both cases.
Sparse Regression Modelling

General Framework and Notation
Our data in these two examples, and many others, is generated from Affymetrix microarrays, and we utilise as a current standard the RMA expression intensity estimates on the log 2 (fold change) scale ([18, 19] ). In either example, write x g,i for the expression of gene g on any sample i, assuming p genes and n independent samples. Then write x i for the column p−vector of expression on sample i, and set X = [x 1 , . . . , x n ]. In notation, all vectors are column vectors, so that x i is the 1 × p row vector, for example, and ⊥ ⊥ denotes conditional independence.
In a regression or designed experiment context, we assume
where µ is a p−vector of constant intercept terms, h i is a known d−vector of covariates for sample i, with j th element h j,i , B is the p × d matrix of regression parameters, ν i is a p−vector of assumedly normal error terms, and ν i ∼ N (0, Ψ) independently where Ψ is the p × p diagonal matrix of elements ψ g (g = 1, . . . , p). Write µ g for the g th element of µ, β g for the g th row of B, and β g,j for the j th element of β g ; the {gene g, sample i} univariate regression is then
The design vector h i may include dummy variables representing the levels of experimental factors and the observed values of measured covariates. Sparse regression modelling is defined by classes of priors on B. The other prior components are the prior for µ, typically taken as independent normals for the elements µ g , and that for the unexplained components of variance ψ g . The latter represent biological, technical and measurement error that are idiosyncratic to each gene. With Affymetrix RMA data, experience with many data sets indicates technical variation in the range of about 0.1-0.5, with values around 0.2-0.3 being quite typical. For such data, then, values of ψ g will typically range across 0.01-0.25 or thereabouts, so providing the basis for prior specification. A standard specification consistent with these guidelines -while rather diffuse -is used in the examples here; this is a common gamma prior with shape 5 and scale 1 for each of the ψ −1 g .
Sparsity Priors
Sparsity modelling aims to induce (many) zeros in the high-dimensional ("tall and skinny") parameter matrix B, reflecting the view that the effects of covariates will be sparse. An intervention or measured covariate may relate to a number of genes -"downstream" genes in a pathway intervention experiment, for example -but many other genes will be unrelated. This complements the statistical view of parsimony in modelling -that is, we aim to identify as few parameters as the data and context require to adequately represent the observed patterns in the expression profiles. The traditional ideas underlying Bayesian "point-mass mixture" prior/models are then absolutely natural. Several groups have used this approach in expression genomics (e.g., [20, 21, 22, 23, 24, 25] ), as did [3] in the context of latent factor models.
Motivated by large-scale expression studies, this thinking and methodology has recently been extended with new hierarchical specifications for such "point-mass mixture" priors ([1] ). An example of the new class of general models is
conditionally independently over genes g and covariates j. Here δ 0 (·) is a point-mass at zero, N (·|m, t) is the normal prior of mean m and variance t, and the covariate-specific parameters τ j control the levels of variation in the magnitudes of the non-zero |β g,j |. Importantly, this new model has individual { gene g, covariate j } association probabilities π g,j ; that is, π g,j is the probability gene g is associated with covariate j. Write Π = {π g,j } for these p×d probabilities. The new class of priors in [1] embodies the view that many genes will have zero (or very small) prior probability of association with any one covariate; we simply do not know which genes do, and which do not. The natural hierarchical model to reflect this view is
where Be(·|sr, s(1−r)) is the beta prior (with mean r and variance r(1− r)/(1 + s)) and the covariate-specific probabilities ρ j are assumed to be drawn from a common specified prior ρ j ∼ Be(ρ j |av, a(1−v)). Note that, while each gene-covariate pair now has its own individual probability π g,j of an effect, marginalizing over these parameters shows that rρ j is the implied population base-rate of non-zero effects for covariate j. Posterior analysis leads to the evaluations of, among other things, the p × d posterior probabilities Π * = {π * g,j } where π * g,j = P r(β g,j = 0|X); these reflect individual gene-covariate shrinkage effects, and may be used to rank and select genes showing association with covariate j. The modelbased approach naturally shrinks π * g,j towards zero for genes showing little evidence of association with covariate j, while estimating the ρ j and "shrinking" the non-zero π * g,j towards the estimated base-rate rρ j . This provides the automatic adaptation to the many inherent "point null (at zero) versus continuous alternative" hypotheses being evaluated -a key and critical strength of the Bayesian approach, obviating the need for any ad-hoc (and post-hoc) multiple testing/comparison consideration.
We stress that this hierarchical model is quite different to the traditional approach -it represents an hierarchical/random effects extension of the usual point-mass mixture prior approach, inserting an additional "layer" between the individual gene-covariate parameters π g,j and the implicit underlying population base-rate of non-zero β g,j effects. Now, by marginalisation over the π g,j in equation (1.3) we obtain
(1.5)
This population-level model has the usual point-mass mixture form, with a base-rate rρ j of non-zero covariate effects for covariate j. Critically, however, in the full model each gene-covariate combination also has its own prior "base-rate" π g,j that is estimated. Since equation (1.4) permits zero values, the posterior will then estimate the data-based support for π g,j = 0 individually. This key feature, induced by the new hierarchical model component, can lead to practical improvements over the standard Bayesian approach in acting against false discovery, especially in contexts where the base-rate is likely to be relative large. By inserting the additional hierarchical layer between the population base-rate of non-zero effects and the individual-level effects, the extended model is able to more adequately shrink towards zero through the induction of zeros under the prior, and hence posterior, for the π g,j . As a result, the hierarchical model is more conducive to separation of the real signals from noise, and will act conservatively -reducing false discoveryrelative to the traditional prior. An example in the next section, and displayed in Figure 1 .1, very clearly highlights this.
The model of equations (1.3) and (1.4) is completed with priors for the variances τ j , taken as conditionally conjugate inverse gamma distributions. Bayesian analysis is performed using MCMC methods to produce samples from the posterior distributions for all model parameters: µ, B, Ψ and the τ j . Full MCMC details are given in [1]. For our purposes here, MCMC analysis produces full posterior samples for all model parameters, now including the critical posterior "significance" parameters in the p × d matrix Π * = {π * g,j }, as well as µ, B, Ψ and the {ρ j , τ j : j = 1, . . . , d}. Additional important summaries involve posterior samples of the (β g,j |β g,j = 0, X). Prior specification is completed through assignment of values to the beta prior hyper-parameters (s, r) and (a, v), as well as prior hyper-parameters for independent gamma priors for the ψ −1 g for each g = 1, . . . , p as earlier mentioned; the examples here use (s, r) = (10, 0.9) and (a, v) = (200, 0.001) for these beta priors.
Example: Oncogene Intervention Experiments
The oncogene intervention data provides illumination. The experimental groups represent up-regulation, using viral transfection, of key oncogenes MYC, SRC, b-catenin, E2F3, H-RAS, Np63α, AKT1, E2F1 and PIK3Ca. Several of these genes play transcriptional roles related to the complex Rb/E2F pathway [26, 27] that is pivotal in regulating cell cycle progression, cell proliferation and cell death (apoptosis). The E2F family of transcription factors is particularly key in this complex of interacting pathways, and one interest relates to differential function for members of the E2F family. The design is a simple one-way classification: one control group with 15 samples (biological replicates), and 9 separate intervention groups with between 7 and 10 replicates per group, for a total of n = 97 samples. So µ g is the average (log2, RMA) expression for gene g in the non-intervention control group, and the d = 9 parameters in β g define changes in level relative to control in each of the 9 intervention groups. Across all genes, most of the β g,j parameters will be zero; the analysis aims to isolate gene-factor combinations with non-zero parameters to identify resulting groups of genes transcriptionally regulated via the cascade of activation initiated for each intervention.
Group j = 2 represents the MYC interventions, for example. highlighting the impact. To verify and empirically validate the view that the traditional model typically fails to induce enough shrinkage -and over-estimates the numbers of "significant" effects as a resultsimilar analyses have been performed in a series of simulation studies in which synthetic data have been generated from the model as defined. Pervasively, the numbers of inferred non-zero parameters -in terms of high values of the posterior probabilities of non-zero values gene-bygene -are systematically over-estimated under the traditional analysis and much more adequately estimated using the new sparsity prior.
Sparse Regression for Artifact Correction with Affymetrix Expression Arrays
Context and Model
Data from all microarray studies is contaminated by non-biological noise from a multitude of sources. Low level processing and normalisation methods aim to address and either correct for or model some of the issues of sample-to-sample, and in some cases gene-sample specific, variation. However, high-throughput expression technologies are still effectively first-generation and the resulting data can often exhibit profound levels of artifactual noise and systematic experimental biases that are induced by small, random and unpredictable changes and fluctuations in experimental controls (hybridisation temperatures, salinity, etc), assay reagents, technician practices, equipment settings and so forth. Complex patterns of such artifactual variations can impact on the resulting estimates of expression levels of many genes, but leave many others unchanged; variation in sequence structure (such as GC content) of oligonucleotides defining Affymetrix probe sets is just one reason for gene-sample-assay specific variation in resulting expression intensities that require consideration. When a study on one microarray platform is performed over time, perhaps involving different technicians, stations/machines within a laboratory or even different laboratories, and almost surely different batches of arrays and reagents, the resulting differences across sample expression profiles will often have major time-ofstudy effects. Such effects will be reflected in many but not all genes, with a multi-dimensional complexity to the pattern of the effects across many genes that can dominate the inherent biological variation that is the target of the study. Issues of comparability of expression results are high-profile in discussions of the potential for microarrays in clinical testing (e.g, [28] ), but in more routine applications the issues they generate can be easily underestimated. Low level processing and normalisation aids in correcting for such artifacts, but very often data will remain contaminated-often substantially so -by these "assay artifacts". Hence the need for follow-on statistical models to explicitly address assay artifacts as components of analysis. Affymetrix arrays include probe sets for a number of housekeeping genes and also "maintenance" genes -genes that robustly show constant levels of expression over a diverse set of (in our case, human) tissue studies, and that serve as normalisation controls. Most studies ignore these normalisation controls and use data from the housekeeping genes as laboratory controls only to be informally checked as part of the overall quality assessment. These probe sets can provide read-outs of assay artifacts, and serve as covariate information to model out components of the complex artifactual distortions as a result. If substantial numbers of these normalisation control genes exhibit common patterns of systematic variation over samples at meaningful levels, and if patterns of similar form show up in levels of expression of subsets of other genes, then the normalisation gene set can provide regression-based corrections for those gene subsets. Assay artifacts will generally impact multiple subsets of genes in differing ways, but leave many genes uncontaminated. As a result, we need multiple such factors as regression covariates, and a model that allows for parsimonious -and sparse -estimation of the regression coefficients of these control factors across the thousands of genes on the array. Clearly, the sparse regression context here is ideal, and underlies an approach to gene-sample specific, model-based artifact correction.
The model in [1] utilises multiple principal components of the set of normalisation control probes, and a selection of the housekeeping probes, as covariates; thus the regression vector h i includes these "normalisation factors" as specified values, in addition to whatever other design and covariate structure is in the model. The analysis already described then applies directly to estimate the regression coefficients on these factors under the same sparsity prior; now, the rate π j applying to any one (j) of the normalisation factors represents the proportion of genes showing association with that factor; a gene with a non-zero and higher value of π * g,j is then identified as exhibiting variation over samples that is in part related to the assay artifact reflected in the normalisation factor j. The model thus provides the ability to isolate these effects from the other components of the regression. Evidently, if ignored these effects may obscure underlying biological structure, leading to lost signals; potentially more perniciously, it may also generate false discovery through the suggestive appearance of significant effects that are in fact strongly associated with gene-study specific artifacts. The oncogene experiment data provides useful examples. Figure 1 .2 displays the first 8 principal components from the normalisation control genes (in this case, 100 probe sets on the Affymetrix U133+ microarray). Systematic and stochastic assay artifacts are ap- parent in what should, in principle, be stable levels of expression of these summaries of control probes. The evident systematic differences between the two sets of replicate control samples in this data set (the initial black open and filled circles) provides information relevant to global gene-sample specific normalisation in that many gene probe sets reflect similar systematic differences. These two different control samples were in fact generated and assayed several months apart, so that different assay conditions are surely why the two samples are different in terms of normalisation factors. The observations in purple represent the RAS intervention samples; clear distortions in the control probes are evident in the second normalisation factor for that group alone. The final set of 37 sample observations, coded yellow to blue, were intervention experiments performed and assayed several months after the first set, and the need for correction of samples is clear. Additional features representing apparent artifactual effects appear in additional principal components of the normalisation probes, as the image display in Figure  1 .2(c) indicates. The model fit to this gene is explored further in Figure 1 .3. PEA-15 (PED) is a phosphoprotein that mediates apoptosis and plays roles in the molecular mechanisms of chemoresistance in cancer [29, 30] . The action of PEA-15 is known to depend on phosphorylation by AKT1, though AKT1 does not play a role in regulation of expression levels of PEA-15. On the other hand, PEA-15 is a direct target for regulation by members of the E2F family of transcription factors, with known promoter binding sequence for E2F (the E2F family members share a common binding site). Hence PEA-15 is anticipated to respond to one or more of the E2F interventions but to our knowledge should not show a transcriptional response as a result of any of the other interventions. As noted earlier, the data show strong association with the temporal sequence of the sample generation, real differences between the two sets of control samples and structure related to the assay artifact patterns in the control components. Figure 1 .3(a) displays the original RMA expression levels. Superimposed on frame (a) are horizontal lines representing the estimated levels of expression within each of the groups in the sparse ANOVA analysis that ignores the normalisation issue. Frame (b) displays corrected levels from the sparse analysis now including the normalisation factors; here the fitted effects of the normalisation factors have been subtracted from the samples displayed. Superimposed are horizontal lines representing the fitted parameters/levels for the intervention effects on expression within each group. This demonstrates the artifactual nature of the expression fluctuations in frame (a) and how the control factors correct those effects and are able to recover the apparent real transcriptional response of PEA-15 to the up-regulation of E2F3 (the central group of samples, coloured cyan). That there is no corresponding effect in the E2F1 group (the penultimate group of samples, coloured red) is suggestive of differential function in transcriptional control of PEA-15 within the E2F family of transcriptional factors, consistent with the known diversity of functional roles across that family [26, 7] . Evidently, ignoring the assay artifact issue would, in this case, lead to substantial false discovery with frame (a) suggestive of multiple potential regulators of PEA-15 within the pathways downstream of several of this set of oncogenes, and also a false negative with respect to the role of E2F3. As with other examples, the artifactual differences between the two control sets in Figure 1.3(a) , and the comparability of fitted values in Figure 1.3(b) , provide support for the relevance of sparse gene-sample specific normalisation component.
Example: Oncogene Intervention Experiments
Sparse Latent Factor Models and Latent Factor Regressions
General Model Structure
Sparse latent factor models, as introduced to the statistics community in [3] , represent a natural extension of the sparse regression modelling approach as well as a natural framework for more incisive development of approaches to pattern/signature profiling in expression genomics. The pilot gene expression study in [3] demonstrated the ability of latent factor models -under traditional Bayesian variable selection priors -to improve the identification and estimation of metagene groups and patterns related to underlying biological phenomena. Part of the motivation for that work was, again, directed at generating a more comprehensive statistical framework for flexible modelling of multiple, complex aspects of substructure in expression data, moving from the empirical methods (using singular value decomposition based factors within multiple gene clusters, e.g., [8, 9, 11, 14] ) into more formal models. One of the key recent extensions and innovations in sparse factor modelling ([2]) is the application of the new hierarchical sparse prior modelling approach described and developed above. The extension of the sparse regression model framework of Sections 1.2.1 and 1.2.2 is immediate, as follows.
Extend the model of equation (1.1) with the addition of a latent factor component involving k latent factors. That is,
where the k-vectors λ i are independent random latent factors, distributed as
and A is a sparse p × k factor loadings matrix. As with B, the loadings matrix A will generally have many more rows than columns; the number of factors k will usually be very small compared to the number of genes. Structuring follows prior work with latent factor models in other contexts ([31, 32] ). The preferred structure for A has the upper right triangle of A set to zero, with positive diagonal elements A i,i for i = 1, . . . , k. Sparse matrices A in fact lead to models that do not require identification constraints, but this specific structure is attractive as it permits the selection of the order of the first k variables (genes) in x i as defining "names" for the latent factors.
One interpretation of the extended factor regression model is that of the regression µ + Bh i with an extended "error" term Aλ i + ν i ; this term has zero mean and variance matrix Σ = AA + Ψ, so that the model represents a regression allowing complex patterns of correlation among the errors. In gene expression studies, especially involving observational data sets, this is particularly relevant since the structure of empirical patterns of covariation among genes across samples is generally rather elaborate, far more so than regression models will adequately describe. Complementing this view, in many applications we are interested in the latent factors as a statistical representation of groupings and cross-linkages of subsets of genes that may be biologically interpretable in terms of pathway inter-connections. The notion of latent factor models as estimating and reflecting multiple interacting biological pathways through the associations observed in expression patterns is germane to some of our current studies.
Evidently, the sparsity prior strategy and resulting Bayesian analysis applies directly to this extended model. The sparsity prior of equation (1.3) is simply extended to also apply to the free elements of the factor loading matrix A, with a modification to constrain the diagonal elements to positivity. This then leads to an extension of the MCMC in which the latent factors themselves are also estimated: conditional on values of all latent factors Λ = [λ 1 , . . . , λ n ], the analysis proceeds as in the straight regression model (with the minor change to add the positivity constraint on diagonal entries in A). Within each MCMC iteration, we then simply add in simulations from the complete conditional posterior of Λ given the data and all other parameters, and this is trivially a set of n conditionally independent k−variate normals for the columns of Λ, thereby neatly completing the MCMC setup. This extends the analysis in [3] to the hierarchical sparsity prior as well as to coupled ANOVA/regression and factor models.
Factor Regression Component
Many gene expression studies also involve explanatory associations between expression profiles and response variables (phenotypes). Following [3], we can couple response variables into the sparse regression and factor model framework to develop models in which the response is linked, via a separate regression model that itself may be subject to sparsity prior analysis, to the latent factors underlying gene expression. This again extends to a model-based context the notion of aggregate patterns in gene expression as predictors of outcomes; the latent factors λ i are now the candidate predictors of phenotypic measures on sample/case i in the study. Additional generalisations of the initial framework of [3] are possible, but the example here adopts this approach.
Consider first the case of a continuous univariate response variable, y i on sample i = 1, . . . , n. Linear regression on the latent factor structure underlying expression profiles is then simply incorporated as y i = α + θ λ i + i with independent normal errors. By simply prepending y i to the expression vector x i , we can clearly just extend the model of equation (1.6) to include α as a first entry in µ and the elements of θ as a first row of A. We may choose alternative prior specification for θ, or may just extend the sparsity prior directly. The latter approach is used for the example summarised below. This clearly extends trivially to include more than one response variable, and the example below has three such phenotypes, treated similarly. With such a model extension, analysis proceeds as before with minor changes to the MCMC.
Our example below involves three binary phenotypes, however, rather than continuous measurements. In the above example of a single response, suppose that we actually only observe a binary outcome z i = 0/1. The linear regression framework maps onto this under a probit regression model, in which y i is a latent variable and the errors i ∼ N (0, 1). This extension permits immediate analysis of binary phenotypes, simply extending the MCMC to iteratively impute samples of the "missing" latent {y i } together with all other model quantities in the standard manner for Bayesian binary regression (e.g., [33, 9, 3] ).
Example: Breast Cancer Gene Expression Analysis
An analysis of expression profiles from primary breast tumours is illustrative of this framework, and also ties into current goals in breast cancer expression genomics. Some summaries of analysis of n = 212 samples appear in Figures 1.4 , 1.5 and 1.6. This data comes from a larger sample of expression profiles on breast tumours from the Sun-Yat Sen Cancer Center in Taipei ([11, 15] ). The analysis here involves p = 500 genes, many of which are related to key breast cancer hormonal and growth pathways -and the interactions of multiple such pathways -especially those linked to oestrogen through the ER (oestrogen receptor) pathway, the very strongly related PR (progesterone receptor) pathway, and the HER2/ERB-B2 proteins. ER and HER2 are each the target of current hormonal therapies in breast cancer. One interest in this application area is improved assays of levels of activation of these pathways, and this raises the question of gene expression-based characterisation as alternatives, or adjuncts, to the traditional immunohistochemical (IHC) assays. For these samples, the IHC assays provide (imperfect and noisy) binary outcomes: 0/1 for each of ER+/−, PR+/− and HER2+/−. The example model for x i is equation (1.6) with an intercept and the first 5 normalisation factors from this data set defining h i so that d = 5. We then have k = 14 latent factors defining the dimensions of λ i . Repeat analysis with more latent factors leads to the additional factors having very few loaded genes, so that the analysis essentially cuts back to that summarised. In addition, we couple in the three binary phenotypes as responses, using probit regression components as described above. has the capacity to adapt to artifactual as well as biological structure in patterns of covariation among genes, and this is a common experience in a number of our studies. Here some of the latent factors, especially those with fewer significantly loaded genes, evidently reflect artifacts that the Affymetrix normalisation control genes are simply not picking up. The ability of the factor model to "soak up" such structure is a strength of the approach. The second frame in Figure 1 .4 represents the same thresholded probabilities but now just for the k = 14 latent factors. Factors are reordered here to give a cleaner visual impression of the implied sparsity of the structure and the "cross-talk" between factors represented by genes significantly loaded on more than one factor.
Other factors very clearly reflect breast cancer biology and the ER/PR and HER2 pathways. This can be examined by listing genes most highly weighted on each factor, taking into account the absolute values of estimated β g,j , and then examining these subsets of genes for known biological function. This analysis generates two factors replete with known ER-related genes, of which factor #2 is dominant in terms of exhibiting many ER-related genes and also strongly discriminating tumour samples based on the reported ER+/− IHC status (see Figure 1 .5). One other factor, factor #1, significantly loads on the several probe sets for HER2/ERB-B2 as well as a small number of genes known to be regulated by or co-regulated with HER2; this therefore defines a primary "HER2 factor". That these factors arise from the analysis, reflecting the major structure these pathways induce in gene expression patterns, indicates that there should be strong associations with the ER and HER2 IHC phenotypes through the coupled factor regression model component; this is evident in Figure 1 .5. The relationship for PR is similarly well defined, as it is very highly correlated with ER and so well delineated by the factors that reflect ER pathway activation levels.
A final point relates to decompositions of gene expression. Figure 1 .6 plots expression levels for one gene -a probe set representing Cyclin D1 on this microarray -across samples. Also plotted, on the same vertical scale, are the fitted effects of two factors for which π * g,j > 0.99 for this gene, factors 2 and 9, and the fitted residuals across the samples for this gene. The model represents a direct decomposition of the data into components contributed by the factors plus residual; the graph illustrates the key aspects of this decomposition for this gene. These two factors contribute comparably to the variations in expression of Cyclin D1 across the breast tumours. Factor 2 is an ER factor, discussed above. Cyclin D1 is a critical gene in cell cycle regulation, acting to phospho- rylate the Rb protein and hence aid cell development and proliferation by relaxing inhibition of the E2F transcriptional machinery. Thus some component of expression variation reflects cell cycle activity unrelated to ER. However, Cyclin D1 is also known to be directly involved in the ER pathway; ER is a cell-type specific inducer of Cyclin D1, and Cyclin D1 antagonises repressors of ER. Hence we have a clear biological rationale and interpretation of the two factors arising from the statistical analysis. Indeed, factor 9 has only a very small number of significantly loaded genes, and the three most highly loaded (with estimated π * g,j very close to 1, and the highest estimated loading parameters) are three Affymetrix probe sets representing Cyclin D1; i.e., factor 9 is a cell cycle related "Cyclin D1" factor that is unrelated to ER. Fig. 1 .6. Plot across breast tumour samples of levels of expression (X) of the gene Cyclin D1 (from the PRAD1/CCND1 probe set on the Affymetrix U95a microarray, one of three probe sets for Cyclin D1 on this array). Plots F2, F9 and E represent the estimated (posterior mean) effects of two of the latent factors and the fitted residual for this gene from the multivariate factor regression model. The four plots are on the same vertical scale, so indicating the breakdown of the expression fluctuations for Cyclin D1 according to contributions from, primarily, these two factors. Factor 2 is the primary ER factor, and factor 9 a factor defined by the three probe sets for Cyclin D1.
Concluding Comments
Gene expression genomics is only one area of modern biotechnology in which the capacity to generate higher-resolution data on increasingly higher-dimensional variables continues to expand. In this and other areas, the concept of sparsity in mathematical and statistical models is central; the ability to induce sparse structure in increasingly highdimensional and complex models will be more and more critical to scalability of statistical methods. The basic concepts and machinery of Bayesian hierarchical modelling are most relevant, and our theme here -hierarchical modelling with sparsity inducing priors -is highlighted by a number of gene expression genomic examples. Our references above include additional developments in sparse regression and factor modelling, with computational developments as well as applications. There are also close connections with sparse graphical modelling for display and interrogation of multivariate structure in gene expression contexts ([34, 35, 36] ), a related area of current research interest in terms of both statistical methodology and genomic application. The linking of linear and binary/probit regression to factor models are of course just examples of broader classes of models for gene expressionbased prediction of clinical or physiological phenotypes. Similar extensions permit analysis of censored survival data, which is a central consideration in many genomic studies (e.g., [6, 15] ). For example, latent variable imputation also easily leads to an approach to survival regression in which the underlying survival times (such as cancer recurrence or death, for example) are assumed conditionally log-normally (or log-T) distributed. Right-censored cases can then be treated by including the "missing" survival times as latent variables to be imputed, parallel to the treatment of the "missing" normal latent variables underlying binary data. Additional extensions utilising non-normal survival models, including Weibull regression models ([15] ) for example, are also amenable to treatment in this framework, though such developments will require customised extensions to the MCMC analysis.
Finally, executable code implementing the combined sparse factor regression models and methods presented here is freely available for interested researchers, and can be found at www.isds.duke.edu/˜mw under the software link.
